HIV self-testing (HIVST) is an effective approach to increase testing uptake. While oral fluid-based HIVST has been rapidly scaled, use of blood-based HIVST remains limited. We evaluated the acceptability, feasibility, and accuracy of blood-based HIVST among lay users in Ho Chi Minh City (HCMC), Vietnam. We conducted a cross-sectional study among HIV testing clients at the HCMC Pasteur Institute from March 2019 to October 2020. Participants received one HIVST kit and performed the test in front of an observer. The observer used product-specific questionnaires to collect information on the HIVST process, test results, experiences. The participants’ interpretations of HIVST results were compared to health staff’s interpretations and gold standard laboratory EIA reference tests. Of 2,399 participants who accepted HIVST, 64.7% were men, 62.1% aged 25–49 years, 53.5% had a higher education level, 41.4% were employed, and 35.6% were first-time testers. The vast majority (94.4%) desired to use the test in the future, and 93.9% reported willingness to recommend the test. The majority (90.8%) of participants successfully completed the self-test. One factor associated with successful completion was higher education level (aOR = 1.85; 95% CI: 1.32–2.61); while participants self-testing with SURE CHECK (aOR = 0.21; 95% CI: 0.12–0.37), INSTI (aOR = 0.23; 95% CI: 0.13–0.39), and BioSURE (aOR = 0.29; 95% CI: 0.17–0.51) or being unemployed, retired, or doing housework (aOR = 0.45; 95% CI: 0.25–0.82) were less likely to perform the test successfully. Agreement of positive and negative HIVST results as interpreted by participants and health staff was high (98.1% and 99.9%, respectively). Sensitivity and specificity of the evaluated HIVST were 96.43% (95% CI: 93.62–99.23) and 99.9% (95% CI: 99.75–100), respectively. Our findings confirm that blood-based HIVST is highly acceptable, feasible, and accurate. This evidence informs scale-up of HIVST to increase uptake of essential HIV prevention and treatment services.
Vietnam faces a hyperendemic burden of hepatitis B virus (HBV) infection, but the prevalence of occult HBV infection (OBI) and its underlying molecular mechanisms in healthy populations remain poorly understood. This study aimed to characterize the serological and molecular HBV profile of a healthy Vietnamese adult cohort in Southern Vietnam. We assessed the prevalence of occult HBV infection (OBI) and HBsAg-positivity (serving as a proxy for probable chronic infection). In this cross-sectional study, 397 healthy adults from Southern Vietnam underwent serological screening for HBsAg, anti-HBs, and anti-HBc. All participants were screened for HBV DNA using a high-sensitivity PCR assay (LOD ≥ 5 IU/mL). For all viremic cases, the full Pre-S/S region was sequenced to determine genotype and characterize escape mutations. We uncovered a high prevalence of both HBsAg-positivity (17.6%) and OBI (9.3% HBsAg-negative, HBV DNA-positive). Serological analysis revealed a massive, age-dependent reservoir of past exposure (63.7% anti-HBc) characterized by a high and increasing prevalence of the anti-HBc only profile (31.5%), a key serological marker for OBI. This trend contrasted sharply with a steep age-related decline in protective anti-HBs. The viral landscape was dominated by genotypes B (73.8%) and C (26.2%), with sub-genotypes B4 and C1 being the most prevalent. Critically, individuals with OBI carried a significantly higher burden of S gene escape mutations compared to those with HBsAg-positivity (p < 0.001). Canonical escape variants, including sG145R (21.6%), sK141R/T/E/Q (24.3%), and sT116N/A/I/S (18.9%), were exclusively or highly enriched in the OBI group. A LASSO-logistic model based on this mutational profile successfully predicted occult infection with high accuracy (AUC = 0.83). A substantial hidden reservoir of occult HBV infection exists within the healthy adult population of Vietnam, driven by a high burden of S gene escape mutations. These findings highlight the significant limitations of conventional HBsAg-only screening. They also underscore the need for comprehensive molecular surveillance to address the true scope of HBV viremia, hopefully enabling a reduction in hidden transmission of clinically significant viral variants.
20 July 2023 in HIV Infection and Immunosuppressive Disorders
Background. In Vietnam, there has been an increase in efforts to monitor and prevent mother-to-child transmission of HIV since 2013. However, data on HIV drug resistance among HIV-1 infected children younger than 18 months of age remain limited. The study fills a critical knowledge gap by providing important insights into the prevalence of resistance among this population in the Southern and Central Highland provinces of Vietnam.Objective. This study aimed to determine the prevalence of HIV drug resistance and patterns of mutation among treatment-naïve children under the age of 18 months who had been recently diagnosed with HIV.Material and methods. Between May 2017 and May 2021, stored remnant DBS samples were collected from children under the age of 18 months who had been diagnosed with HIV through routine Early Infant Diagnosis testing in Central Highland and Southern Vietnam. HIV drug resistance tests were performed, and interpretation was done using the Stanford algorithm.Results and discussion. Overall, 111 samples with eligible viremia for sequencing (ct value <31) were collected for genotyping, in which 110 protease sequences and 106 complete reverse transcriptase regions were generated. Males were 61.3%, 52.3% were aged from 6 weeks to <9 months and 37.0% were breastfed. Access to mother-to-child intervention was reported in 60.3%. The accumulation of major drug resistance mutations was found in 43.8% of infants and most of them were resistant to Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) (37.7%). High-level resistance to Nevirapine was present in 40% of cases. The risk factors associated with NNRTI resistance were antiretroviral prophylaxis (aOR: 3.68, 95% CI: 1.83–7.45) and breast-feeding history (aOR: 2.16, 95% CI: 1.03–4.53). CRF01-AE was the predominant subtype.Conclusion. The study identified a high prevalence of resistance to NNRTIs among HIV-1 infected infants less than 18 months of age in the Southern and Central Highland provinces of Vietnam. This highlights the need for further investigation and a potentially larger national survey to confirm the extent of this issue in Vietnam. Our findings support the current actions of the Vietnam Ministry of Health, which prioritize integrase inhibitor-based regimens as the preferred first line of ART for children to achieve durable viral suppression and minimize treatment failure. This approach aligns with the recommendations of the World Health Organization.
Background: Vietnam has made significant strides in reducing the prevalence of HIV infection and achievements in its antiretroviral treatment program. However, the COVID-19 pandemic and financial challenges in the healthcare system have posed significant obstacles to maintaining effective HIV treatment and monitoring, particularly among vulnerable populations. This study aims to evaluate the situation of HIV drug resistance among patients who have experienced treatment failure in the Mekong Delta region and to compare data from 2019 to 2022. Methods: The study material was blood plasma samples from HIV-infected individuals with ART failure: 316 collected in 2019 and 326 collected in 2022. HIV-1 genotyping and mutation detection were performed based on an analysis of the nucleotide sequences of the Pol gene region. A total of 116 HIV-infected individuals with virological failure in 2019 and 2022 were assessed for HIV drug resistance. Results: The study revealed a high proportion of participants with viral loads exceeding 1000 copies/mL, significantly increasing from 12.0% in 2019 to 23.9% in 2022 (OR = 2.3; p = 0.0001). HIV drug resistance mutations were detected in 84.21% of cases in 2019 and 92.59% in 2022. The prevalence of concurrent resistance to NRTIs and NNRTIs was 37.5% and 30.13% in 2019 and 2022, respectively. There was a statistically significant decrease in NNRTI resistance (OR = 0.32, χ2 = 5.43, p < 0.05). In contrast, multi-drug resistance to protease inhibitors rose from 18.52% to 45.21% (φ* = 0.00403, p < 0.05). Triple-class resistance was identified only in 2022 (17.81%). The most common mutations included M184I/V, D67N, K103N, Y181C, and V82A/S/T, with D67N rising significantly from 3.13% to 21.92%. The predominant subtype was CRF01_AE. Conclusion: A high prevalence of viral non-suppression and HIV drug resistance was observed among patients in the Mekong Delta region, particularly after the onset of the COVID-19 pandemic. Our study highlights the ongoing challenges that the HIV/AIDS treatment program in Vietnam must address in the post-pandemic period to sustain its success and achieve the goals of the country’s HIV prevention strategies.
1 June 2026 in Russian Journal of Infection and Immunity
Background. Southern Vietnam is hyperendemic for Hepatitis B virus (HBV) infection, yet comparative data on the full spectrum of HB serological and molecular profiles — including susceptibility and occult infection — between HIV-infected and healthy adults in this setting remain limited. The aim of this study was to comprehensively evaluate and compare the serological and molecular markers and profiles of Hepatitis B virus infection between HIV-infected patients and apparently healthy adults in Southern Vietnam. Materials and methods. A comparative cross-sectional study was conducted on 713 participants (316 HIV-infected and 397 healthy adults). Blood plasma samples were screened for HBsAg, anti-HBs IgG, and anti-HBc IgG markers. HBV DNA testing was performed using a high-sensitivity in-house PCR. Multivariable logistic regression and interaction analyses were employed for comparative analysis. Results. HBsAg prevalence was comparably high in both the healthy (17.6%) and HIV-infected (16.1%) cohorts, reflecting early-life exposure. However, the HIV cohort exhibited a significantly higher rate of seronegativity for all markers (43.0% vs 16.1%; p 0.001). The burden of OBI was two-fold higher in the HIV group (17.1%) compared to healthy controls (9.3%; aOR = 2.00). Notably, 6.65% of seronegative HIV patients (“triple-negative”) tested positive for HBV DNA, a prevalence 13-fold higher than in controls (0.50%). Age-trend analysis revealed that while healthy adults accumulated immunity with age, HIV-infected individuals exhibited “immune erasure” and seroreversion, leading to the loss of protective antibodies and increased risk of occult infection in older age. Conclusion. Our study documents important differences in HBV serological and molecular profiles between HIV-infected patients and healthy adults in a hyper-endemic setting. Our cross-sectional data are consistent with HIV-associated perturbation of humoral immunity, manifested by higher rates of seronegativity. The detection of triple-negative occult HBV infection highlights a limitation of serology-only screening. In endemic settings, clinicians and public health programs should therefore consider risk-stratified approaches that incorporate molecular testing, particularly for high-risk subgroups where universal screening is not feasible.
Hepatitis B virus (HBV) infection remains a major concern among people living with HIV (PLWH), particularly in high-endemic settings such as Vietnam. The study evaluated the serological and molecular characteristics of HBV among PLWH receiving antiretroviral therapy (ART) in southern Vietnam. A cross-sectional study was conducted among 316 HIV-infected patients receiving ART. Serological markers (HBsAg, anti-HBs IgG, and anti-HBc IgG) and HBV DNA were assessed using highly sensitive assays, and the Pre-S1/Pre-S2/S regions were sequenced for genotype and mutation analysis. Associations were evaluated using appropriate statistical methods. HBV DNA was detected in 32.6% of the patients, whereas HBsAg was present in only 16.1%. The most common serological profile was susceptibility (36.4%), followed by occult HBV infection (OBI) (17.4%), including 6.6% with completely seronegative OBI, and chronic HBV (CHB) (15.8%). Males and older individuals showed a significantly higher risk of CHB (adjusted odds ratio [aOR] = 2.58 and aOR = 1.87, respectively). Genotype B predominated (78.4%) overall, but genotype C was significantly more frequent in OBI than in CHB patients (31.5% vs. 8.3%, p = 0.008). Moreover, the burden of surface S gene escape mutations was significantly higher in the OBI group (p = 0.023). The LASSO model showed a moderate discriminatory ability for predicting OBI status (Area Under the Receiver Operating Characteristic [ROC] Curve [AUC] = 0.76). Lamivudine-associated resistance (rtM204I/V) was the most common RT mutation detected in the overlapping RT/S region. HIV-infected individuals in southern Vietnam face a burden of both CHB and OBI, including a high proportion of seronegative OBI. The presence of seronegative OBI further supports the risk of underdiagnosis when relying only on standard serological markers, and reflects the need for integrated strategies combining highly sensitive serological assays with molecular diagnostics to improve HBV detection among high-risk populations.